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Gastric cancer is one of the most common cancers of the gastrointestinal system, and its overall fi ve-year 
survival rate is still 15 % to 20 %, as it can mostly be diagnosed at an advanced stage. On the other hand, 
although colorectal cancer has a rather good prognosis, mortality is one half that of the incidence.
As carcinogenesis is believed to involve reactive radicals that cause DNA adduct formation, impaired 
repair activity, and weakened tumour suppression, it would help to understand the role of the polymorphisms 
of nucleotide excision repair enzyme XRCC1 and of tumour suppressor gene p53 in gastric and colorectal 
cancers. Our study included 94 gastric cancer patients, 96 colorectal cancer patients, and 108 cancer-free 
individuals as control with the aim to see if there was an association between XRCC1 Arg399Gln and p53 
Arg72Pro polymorphisms and cancer susceptibility. DNA was extracted from peripheral blood cells and 
genotypes were determined using the polymerase chain reaction-restriction fragment length polymorphism. 
Polymorphism p53 Arg72Pro was not associated with either gastric or colorectal carcinoma, while XRCC1 
Arg399Gln was not associated with the increased risk of colorectal cancer. However, XRCC1 homozygous 
Gln allele at codon 399 was associated with 2.54 times higher risk of gastric cancer.
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Genetic factors that alter repair of the damaged 
gastric and colon cell DNA leading to carcinoma have 
still been poorly understood. Accumulation of 
constantly generated reactive species during cellular 
metabolism and extracellular processes may contribute 
to carcinogenesis caused by oxidative DNA damage. 
p53, a tumour suppressor protein encoded in humans 
by the TP53 gene (1) regulates the cell cycle and 
preserves the stability of the human genome to prevent 
cancer initiation (2). It is estimated that almost 50 % 
of cancer cases carry a mutation of the p53 gene (3, 
4). On the other hand, polymorphisms of genes 
involved in multiple steps of carcinogenesis may also 
account for genetic difference in susceptibility to 
gastric and colorectal carcinomas (5). Polymorphism 
in exon 4, in the domain of transactivation of the p53 
protein, results in an amino acid replacement from 
arginine (Arg) to proline (Pro). However, functional 
changes caused by this substitution are unknown. 
Inconsistent results have been found for the Pro variant 
allele of the p53 gene as a risk factor of various cancers 
(5). The X-ray repair cross-complementing group 1 
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(XRCC1) protein is involved in the repair of DNA 
base damage and single-strand DNA breaks. One of 
the common polymorphisms of the gene is at codon 
399. This polymorphism leads to an amino acid 
replacement of Arg with glutamine (Gln) and can alter 
gene function. Previous studies have reported that the 
Gln allele at codon 399 is signifi cantly associated with 
a higher level of DNA adducts (6, 7), increased sister 
chromatid exchange frequencies (8, 9), and increased 
sensitivity to ionising radiation (9). Therefore, the 
presence of homozygous Gln allele may alter cancer 
susceptibility and disease progression. In clinical 
studies, this polymorphism has been associated with 
the risk of several cancers and has also been used as 
a predictor of colorectal, bladder, and gastric cancers 
after chemotherapy (10-12). However, factors such as 
population stratification, ethnicity, and patient 
selection criteria may account for the discrepancies in 
findings. The aim of our study was to investigate the 
relation between p53 Arg72Pro and XRCC1 Arg399Gln 




This prospective randomised study included 94 
consecutive gastric cancer patients [mean age ± 
standard error of mean (SEM): (60.3±1.4) years; mean 
body mass index (BMI): (23.7±0.4) kg m-2; 30 women 
and 64 men], 96 consecutive colorectal cancer patients 
[mean age: (62.1±1.4) years; BMI: (25.7±0.4) kg m-2; 
40 women and 56 men], and 108 cancer-free patients 
[age: (56.3±1.3) years; BMI: (26.9±0.5) kg m-2, 51 
women and 57 men] who were admitted to Gazi 
University, Faculty of Medicine, Department of 
General Surgery for surgical intervention. None of the 
patients had malignant or metabolic disorders, cardio-
pulmonary or metabolic risks that could be an obstacle 
for the surgery. The primary disease of the cancer 
patients was suitable for surgical intervention.
The study did not include patients with immune 
system disorders who could not receive surgical 
treatment or neoadjuvant chemotherapy due to the 
advanced stage of cancer, patients who had malnutrition, 
autoimmune diseases, systemic infl ammatory response 
syndrome, intra-abdominal sepsis,  chronic 
granulomatosis, collagen tissue or neurodegenerative 
diseases.
All participants’ rights were protected and informed 
consents obtained according to the Helsinki 
Declaration. A local ethics committee approved the 
study protocol.
We isolated DNA from peripheral blood of each 
individual by extracting it with sodium perchlorate/
chloroform (13). p53 (GenBank ID: F261892S10) 
Arg72Pro and XRCC1 (GenBank ID: L47234) 
Arg399Gln genotypes were determined using the 
polymerase chain reaction - restriction fragment length 
polymorphism (PCR-RFLP) according to modifi ed 
Table 1 Odds ratios for colorectal cancer according to the genotypes of p53 Arg72Pro and XRCC1Arg399Gln polymorphism
Genotype Control Group Colorectal Cancer Group OR (95 % CI) pn (%) n (%)
p53
Arg / Arg 52 (48.1) 50 (52.1) 1
Arg / Pro 42 (38.9) 41 (42.7) 1.015 (0.569 to 1.812) 0.959
Pro / Pro 14 (13.0) 5 (5.2) 0.371 (0.125 to 1.107) 0.068
n (allele frequency) n (allele frequency)
Arg 146 (0.68) 141 (0.73)
Pro 70 (0.32) 51 (0.27)
n (%) n (%)
XRCC1
Arg / Arg 50 (46.3) 47 (49.0) 1
Arg / Gln 49 (45.4) 37 (38.5) 0.803 (0.448 to 1.440) 0.462
Gln / Gln 9 (8.3) 12 (12.5) 1.418 (0.548 to 3.673) 0.470
n (allele frequency) n (allele frequency)
Arg 149 (0.69) 131 (0.68)
Gln 67 (0.31) 61 (0.32)
OR - odds ratio, CI - confi dence interval
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protocols of Toruner (14) and Kocabas (15), respectively. 
For each individual, 50 ng of DNA was used for the 
amplifi cation reaction. PCR primers for p53 Arg72Pro 
were F 5’-TCCCCCCTTGCCGTCCCAA-3’ and R 
5’-CGTGCAAGTCACAGACTT-3’ and for XRCC1 
Arg399Gln F 5’-CAGTGGTGCTAACCTAATC-3 and 
R 5’-AGTAGTCTGCTGGCTCTGG-3’. Briefl y, for 
p53 Arg72Pro genotyping, 1.5 mmol L-1 MgCl2, 
0.2 mmol L-1 of each dNTP, 0.05 μmol L-1 of each 
primer, and 0.1 U μL-1 Taq polymerase were used to 
perform PCR. Thermal cycling conditions were 94 °C 
for 5 min, followed by 35 cycles of amplifi cation 
(denaturation at 94 °C for 30 s, annealing at 60 °C for 
30 s, and extension at 72 °C for 30 s) and a fi nal 
elongation at 72 °C for 7 min. PCR products were 
digested with Bsh 1236I (Fermentas Company, 
Lithuania) and separated by electrophoresis on 2 % 
agarose gel (14). PCR tube for the genotyping of 
XRCC1 Arg399Gln contained 2 mmol L-1 MgCl2, 
0.3 mmol L-1 of each dNTP, 0.4 μmol L-1 of each 
primer and 0.5 U μL-1 Taq polymerase. Thermal 
cycling conditions were 94 °C for 2 min, followed by 
35 cycles of amplifi cation [denaturation at 94 °C (30 s), 
annealing at 58 °C (45 s), and extension at 72 °C 
(45 s)], and a fi nal elongation at 72 °C for 7 min. PCR 
products were digested with MspI (Fermentas 
Company, Lithuania) and visualised on 2 % agarose 
gel (15). Genotyping results for both polymorphisms 
were confi rmed by DNA control sequences.
Statistical analysis
The results were expressed as mean±SEM, where 
appropriate. The deviation from the Hardy-Weinberg 
equilibrium was checked among cases and controls 
using the chi-square test with one degree of freedom. 
Odds ratios (ORs) with 95 % confi dence intervals 
(CIs) were determined with logistic regression models 
in order to evaluate the association between gastric or 
colorectal cancer and p53 Arg72Pro and XRCC1 
Arg399Gln polymorphisms. Data were analysed using 
the statistical package SPSS, version 13.0 (SPSS Inc., 
Chicago, IL, USA).
RESULTS
Gastric cancer patients, colorectal cancer patients, 
and cancer-free patients were genotyped in order to 
determine p53 Arg72Pro and XRCC1 Arg399Gln 
polymorphisms. None of the genotype distributions 
deviated from the Hardy-Weinberg equilibrium. Neither 
of the polymorphisms was associated with colorectal 
cancer (Table 1). However, the risk of gastric cancer 
was found to be 2.54 times higher in the homozygous 
carriers of variant XRCC1 Arg399Gln allele (Table 2; 
p<0.05). Evaluation by dominant model and model of 
heterozygote advantage for both p53 Arg72Pro and 
XRCC1 Arg399Gln polymorphisms did not reach 
Table 2 Odds ratios for gastric cancer according to the genotypes of p53 Arg72Pro and XRCC1Arg399Gln polymorphism 
Genotype Control Group Gastric Cancer Group OR (95 % CI) pn (%) n (%)
p53
Arg / Arg 52 (48.1) 40 (42.6) 1
Arg / Pro 42 (38.9) 41 (43.6) 1.269 (0.699 to 2.303) 0.433
Pro / Pro 14 (13.0) 13 (13.8) 1.207 (0.511 to 2.853) 0.668
n (allele frequency) n (allele frequency)
Arg 146 (0.68) 121 (0.64)
Pro 70 (0.32) 67 (0.36)
n (%) n (%)
XRCC1
Arg / Arg 50 (46.3) 35 (37.2) 1
Arg / Gln 49 (45.4) 43 (45.7) 1.254 (0.691 to 2.273) 0.456
Gln / Gln 9 (8.3) 16 (17.0) 2.540 (1.008 to 6.397) 0.044*
n (allele frequency) n (allele frequency)
Arg 149 (0.69) 113 (0.60)
Gln 67 (0.31) 75 (0.40)
OR - odds ratio, CI - confi dence interval, *p< 0.05, considered as statistically signifi cant.
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statistical signifi cance in either colorectal or gastric 
cancer (all; p>0.05). On the other hand, the combination 
of the mutant genotypes of p53 Arg72Pro and XRCC1 
Arg399Gln did not increase the risk of colorectal or 
gastric cancer (Tables 3 and 4; p>0.05). Gastric cancer 
risk was 1.91 times higher in men than in women [OR 
at 95 % CI: 1.909 (1.074 to 3.393), p<0.027]. However, 
there was no association between either of the 
polymorphisms and gastric or colorectal cancer when 
evaluated separately for women and men (p>0.05).
DISCUSSION
Eariler studies on the association between p53 
Arg72Pro and XRCC1 Arg399Gln polymorphisms and 
gastric and colorectal carcinomas revealed inconsistent 
results that might be attributed to a number of genetic 
and ethnic factors (16-27). The p53 tumour suppressor 
protein is essential in cell cycle control and maintenance 
of genomic stability (28). Yi et al. (5) propose that 
independent of transcription, p53 favours apoptosis 
in cells with DNA damage (5). The loss of p53 function 
is one of the key factors in cancer development (29). 
The Arg/Pro polymorphism at codon 72 is one of the 
ten polymorphisms that have been detected in human 
p53 so far (30). Sreeja et al. (31) have shown that the 
Pro allele at codon 72 may alter the enzyme activity 
of p53. The Pro allele seems to favour p53 binding to 
p73, a p53 homologue and transcription factor of some 
p53 target genes, which may lead to alterations in the 
activation of some p53-interacting genes (32). 
Regarding to these assumptions, Van Oijen et al. (29) 
have found both the mutation and retention of the Arg 
allele. Bae et al. (33) have shown that a difference at 
a single codon of the p53 gene can alter the protein. 
Moreover, the distribution of p53 codon 72 
polymorphism changes with ethnicity. Studies from 
Switzerland and the USA showed that almost 50 % of 
the population had the Arg/Arg genotype of p53 at 
codon 72 (16, 17). However, two separate studies from 
China established different genotype distributions for 
the p53 Arg72Pro polymorphism (18, 19). According 
to Almeida et al. (34), genotype distribution in a 
Brazilian population was 60 % for homozygous p53 
Arg/Arg, 28.2 % for heterozygous p53 Arg/Pro, and 
11.8 % for homozygous p53 Pro/Pro. Compared to 
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literature data, Turkish population has a similar 
genotypic distribution as Caucasians.
In our study, we have not found any association 
between p53 Arg72Pro polymorphism and increased 
risk of either gastric or colorectal cancer. In contrast, 
Xi et al. (35) found a relation between the increased 
risk of gastric carcinoma and p53 Arg72Pro 
polymorphism and said that bad prognosis was 
associated with p53 mutation. In a Japanese study, 
Hiyama et al. (36) found similar allele frequencies in 
both control and gastric cancer patients. Similarly, an 
Argentine study (20) found that individuals with the 
Pro/Pro genotype had an increased risk of colorectal 
cancer. Evaluating 1000 incident gastric cancer 
patients and 1300 controls, Liu et al. (37) found no 
independent effects of p53 Arg72Pro on gastric cancer 
risk. A study from the USA (38) found no association 
between colorectal cancer and p53 Arg72Pro 
polymorphism, but Jones et al. (39) identifi ed p53 Pro 
allele at codon 72 as a risk factor for colorectal cancer 
in combination with environmental factors. Case-
control studies in Japan and Turkey failed to fi nd a 
relation between the p53 polymorphism and colorectal 
cancer (40, 41).
XRCC1 acts as a central scaffolding protein and 
plays a crucial role in the removal of endogenous and 
exogenous DNA damage (6, 7). Our study has shown 
that the distribution of the XRCC1 homozygous mutant 
genotype in Turkish population is between Asian and 
Caucasian populations, while heterozygous Arg/Gln 
allele distribution in XRCC1 codon 399 was similar 
in both Asian and Caucasian populations (21, 23, 24). 
Surprisingly, we have found a different frequency of 
homozygous mutant genotype of XRCC1 than the 
previous study by Kocabas et al. (15). This contradiction 
might be attributed to different ethnic groups and 
divergent genetic pool in Turkey.
In our study, there was no association between the 
increased risk of colorectal carcinoma and XRCC1 
Gln allele at codon 399. This is in agreement with an 
Italian (25) and an English study (26). In a study with 
207 cancer patients and 621 controls, Jin et al. (42) 
identifi ed the XRCC1 Gln allele at codon 399 as an 
independent factor for colorectal cancer.
Findings on the association between XRCC1 
Arg399Gln polymorphism and gastric cancer are also 
controversial. Studies by Lee et al. (24) and Geng et 
al. (43) in Asian populations, and studies by Huang et 
al. (22) in Polish and by Duarte et al. (21) in Brazillian 
population  found no association while, Capella et al. 
(27) and Ratnasinghe et al. (23) established a 
relationship between the XRCC1 Arg allele at codon 
399 and gastric cancer originating from different 
segments of the stomach. We too have found that 
individuals carrying homozygous Gln allele have a 
2.54 times higher risk of gastric cancer.
In contrast, the combination of the mutant 
genotypes of p53 Arg72Pro and XRCC1 Arg399Gln 
did not alter the risk of either colorectal or gastric 
cancer. This suggests that the homozygous mutant 
alleles in these two unrelated genes do not affect each 
other in such way as to increase the risk of colorectal 
or gastric cancers.
Our study has also established a two times higher 
gastric cancer risk in men than in women, which is in 
accordance with global data (44).
However, there are several limitations to our study. 
Being hospital-based and case-control, it may be 
subject to selection bias. However, this bias is of no 
great concern, as our study focuses on a genotype-
driven interaction rather than an environment-driven 
one. Our results are based on a limited number of 
single-nucleotide polymorphisms and additional, 
larger-scaled studies are needed to determine the 
interaction between genetic and environmental factors 
and the risk of gastric and colorectal carcinomas.
Controversial as they may be, however, our 
findings call for further evaluation of XRCC1 
polymorphism as a risk factor for gastric cancer.
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Sažetak
POVEZANOST IZMEĐU POLIMORFIZAMA XRCC1 ARG399GLN I P53 ARG72PRO S RIZIKOM 
OD RAKA ŽELUCA I DEBELOGA CRIJEVA U TURSKOJ POPULACIJI
Rak želuca najčešći je oblik karcinoma probavnoga sustava, a ukupno mu je preživljenje i dalje 15 % do 
20 %, budući da se većinom dijagnosticira u poodmakloj fazi razvoja. S druge pak strane, premda rak 
debeloga crijeva ima prilično dobru prognozu, smrtnost je i dalje 50 %.
Vjeruje se da je nastanak karcinoma povezan s reaktivnim radikalima koji uzrokuju stvaranje DNA-adukata, 
onemogućavaju popravak DNA te slabe supresiju tumora. Stoga bi bilo korisno razumjeti ulogu 
polimorfi zama gena za enzim XRCC1 koji sudjeluje u popravku isjecanjem nukleotida i tumor-supresorskoga 
gena p53 u nastanku raka želuca i debeloga crijeva. Naše je ispitivanje obuhvatilo 94 bolesnika s rakom 
želuca, 96 bolesnika s rakom debeloga crijeva te 108 kontrolnhih ispitanika (koji nisu oboljeli od bilo 
kojeg oblika raka) s ciljem da se utvrdi povezanost između polimorfi zama XRCC1 Arg399Gln i p53 
Arg72Pro i sklonosti nastanku raka. DNA je dobiven iz stanica periferne krvi, a genotip utvrđen s pomoću 
metode lančane reakcije polimerazom - polimorfi zma restrikcijskih fragmenata na osnovi dužine (PCR-
RLFP). Polimorfi zam p53 Arg72Pro nije se pokazao povezanim s povećanim rizikom od raka želuca ili 
debeloga crijeva niti je XRCC1 Arg399Gln bio povezan s povećanim rizikom od raka debeloga crijeva, 
ali je zato rizik od raka želuca u homozigotnih nositelja ovoga polimorfi zma bio 2,54 puta veći.
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